{"id":10143,"date":"2021-06-02T11:48:44","date_gmt":"2021-06-02T18:48:44","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=10143"},"modified":"2021-06-03T11:49:23","modified_gmt":"2021-06-03T18:49:23","slug":"safety-and-immunogenicity-of-a-recombinant-dna-covid-19-vaccine-containing-the-coding-regions-of-the-spike-and-nucleocapsid-proteins-preliminary-results-from-an-open-label-phase-1-trial-in-healthy-adu","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/06\/02\/safety-and-immunogenicity-of-a-recombinant-dna-covid-19-vaccine-containing-the-coding-regions-of-the-spike-and-nucleocapsid-proteins-preliminary-results-from-an-open-label-phase-1-trial-in-healthy-adu\/","title":{"rendered":"Safety and Immunogenicity of a Recombinant DNA COVID-19 Vaccine Containing the Coding Regions of the Spike and Nucleocapsid Proteins Preliminary Results from an Open-Label Phase 1 Trial in Healthy Adults Aged 19-55 Years"},"content":{"rendered":"<ul>\n<li style=\"font-weight: 400\"><i><span style=\"font-weight: 400\">[Pre-print, not peer-reviewed]<\/span><\/i><span style=\"font-weight: 400\"> An open-label phase 1 trial in Korea for the recombinant COVID-19 DNA vaccine candidates GX-19 and GX-19N (Genexine, Inc.) (n=61) found that geometric mean titers (GMTs) of anti-SARS-CoV-2 antibodies elicited by vaccination were lower than convalescent sera (although higher than pre-vaccination sera). GX-19N-elicited T-cell responses were stronger than GX-19 and were similar in magnitude to T-cell responses from convalescent individuals. Additionally, GX-19N induced spike and nucleocapsid-specific responses containing epitopes also identified in SARS-CoV-2 variants of concern. Solicited adverse events were reported in 52% of participants, all but one of which were mild.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Ahn et al.\u00a0(June 1, 2021). Safety and Immunogenicity of a Recombinant DNA COVID-19 Vaccine Containing the Coding Regions of the Spike and Nucleocapsid Proteins Preliminary Results from an Open-Label Phase 1 Trial in Healthy Adults Aged 19-55 Years. Pre-print downloaded Jun 2 from <\/span><\/i><a href=\"https:\/\/doi.org\/10.1101\/2021.05.26.21257700\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1101\/2021.05.26.21257700<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>[Pre-print, not peer-reviewed] An open-label phase 1 trial in Korea for the recombinant COVID-19 DNA vaccine candidates GX-19 and GX-19N (Genexine, Inc.) (n=61) found that geometric mean titers (GMTs) of anti-SARS-CoV-2 antibodies elicited by vaccination were lower than convalescent sera (although higher than pre-vaccination sera). GX-19N-elicited T-cell responses were stronger than GX-19 and were similar&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/06\/02\/safety-and-immunogenicity-of-a-recombinant-dna-covid-19-vaccine-containing-the-coding-regions-of-the-spike-and-nucleocapsid-proteins-preliminary-results-from-an-open-label-phase-1-trial-in-healthy-adu\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[33],"topic":[31],"class_list":["post-10143","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-vaccines","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/10143","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=10143"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/10143\/revisions"}],"predecessor-version":[{"id":10144,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/10143\/revisions\/10144"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=10143"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=10143"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=10143"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=10143"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}